PAREXEL International Corporation Securities Litigation
On or around 09/20/2017 (Notice of voluntarily dismissal)
Filing Date: July 24, 2017
According to the Complaint, on June 19, 2017, PAREXEL’s Board of Directors (the “Board” or “Individual Defendants”) caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, shareholders of PAREXEL will receive $88.10 per share in cash.
On July 14, 2017, defendants filed a Preliminary Proxy Statement (the “Proxy Statement”) with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.
On September 20, 2017, Plaintiff voluntarily dismissed this action.
Company & Securities Information
Defendant: PAREXEL International Corporation
Industry: Medical Equipment & Supplies
Headquarters: United States
Ticker Symbol: PRXL
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Louis Scarantino, et al. v. PAREXEL International Corporation, et al.